Matching articles for "Bydureon BCise"
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • August 5, 2024; (Issue 1708)
...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
In Brief: GI Effects of GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • November 27, 2023; (Issue 1690)
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2...
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes
and weight management (see Table 1), but they delay
gastric emptying and commonly cause nausea and
vomiting. Gastroparesis and bowel obstruction (ileus)
have also been reported with their use.
Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)
The Medical Letter on Drugs and Therapeutics • August 21, 2023; (Issue 1683)
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor empagliflozin has been available for years
alone (Jardiance – Boehringer Ingelheim) and in
combination with metformin (Synjardy) to improve
glycemic...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor empagliflozin has been available for years
alone (Jardiance – Boehringer Ingelheim) and in
combination with metformin (Synjardy) to improve
glycemic control in adults with type 2 diabetes. Both
products have now been approved for use in children
≥10 years old. Empagliflozin is the second oral drug
to become available in the US for treatment of type
2 diabetes in children; metformin has been available
since 2000 for this indication. The injectable
glucagon-like peptide-1 (GLP-1) receptor agonists
liraglutide (Victoza) and extended-release exenatide
(Bydureon BCise) are also approved for use in children
≥10 years old.